Acceleron Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XLRN Nasdaq 8731 http://www.acceleronpharma.com/ 31.48 Stock Down -0.64

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acceleron Pharma Inc

Acceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017 - Jul 27th, 2017 5:00 am
Billions of Dollars on the Line for Celgene With These 3 Small Biotechs - Jul 9th, 2017 5:28 am
Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association - Jun 23rd, 2017 12:30 am
Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association - Jun 23rd, 2017 12:30 am
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug - Jun 15th, 2017 6:26 am
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II - Jun 14th, 2017 1:25 pm
Can This Small Biotech Be Saved By Developing Anemia Drug? - Jun 13th, 2017 2:18 pm
Acceleron investors react to trial flop with a shrug, then cheers - Jun 13th, 2017 9:15 am
Acceleron: When Bad News Is Really Good News - Jun 13th, 2017 8:02 am
Biotech Movers: Acceleron, Clovis, Coherus - Jun 13th, 2017 7:28 am
Acceleron Pharma Slides on Missed Mid-Stage Results - Jun 13th, 2017 7:10 am
Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma - Jun 12th, 2017 2:30 pm
ETFs with exposure to Acceleron Pharma, Inc. : June 5, 2017 - Jun 5th, 2017 12:56 pm
Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : June 5, 2017 - Jun 5th, 2017 6:41 am
Celgene & Acceleron Complete Enrollment on Thalassemia Drug - Jun 2nd, 2017 9:52 am
Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 - Jun 2nd, 2017 8:03 am
Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia - Jun 1st, 2017 5:30 am
Acceleron to Participate in Two Healthcare Investor Conferences in June - Jun 1st, 2017 5:00 am
Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association - May 18th, 2017 5:00 am
Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : May 11, 2017 - May 11th, 2017 5:52 pm